Clinical Trial Investigator Agreement
Drafts U.S. clinical trial Investigator Agreements between sponsors/CROs and principal investigators or institutions for FDA-regulated drug, biologic, or device studies. Enforces 21 CFR Parts 50, 56, 312/812, ICH GCP E6(R2), HIPAA, IRB requirements, FMV/AKS payment compliance, data integrity, publication rights, IP ownership, indemnity, and audit access. Use when drafting investigator agreements, PI agreements, clinical trial site agreements, or sponsor-PI contracts; trigger keywords: investigator agreement, clinical trial agreement, PI agreement, FDA, IND, IDE, IRB, GCP, clinical research agreement, site agreement.
Clinical Trial Investigator Agreement
Drafts a sponsor–PI/site agreement that operationalizes FDA, IRB, and GCP obligations for a specific clinical trial.
Prerequisites
- Protocol number, title, version date, phase, endpoints, enrollment target.
- Investigator's brochure or device manual; investigational product handling requirements.
- Sponsor identity, CRO involvement, contracting structure (institution, PI, or both).
- Site legal name, state law, institutional policies, and any required template language.
- PI credentials, sub-investigators, study team roles.
- Budget and payment model (per subject, per visit, milestones); invoicing rules.
- IRB details, consent/assent forms, recruitment materials, vulnerable population plan.
- Data ownership, publication expectations, IP posture, sample handling.
- Insurance positions and indemnity constraints (public entities, academic limits).
Output Structure / Process
- Intake — targeted questions; confirm drug/biologic (21 CFR 312) vs device (21 CFR 812) track.
- Draft — follow the section order below, incorporating site-specific policies.
- Exhibits — attach and incorporate by reference.
- Verify — run compliance checks using the tables and checklist below.
Regulatory Baseline
| Topic | Authority |
|---|---|
| Informed consent | 21 CFR Part 50; LAR, assent where required |
| IRB | 21 CFR Part 56; 45 CFR 46 when institution requires |
| Drugs/Biologics | 21 CFR Part 312; IND obligations flow down |
| Devices | 21 CFR Part 812; IDE obligations flow down |
| GCP | ICH GCP E6(R2) |
| Financial disclosure | 21 CFR Part 54 |
| Privacy | HIPAA and state privacy laws |
| Vulnerable populations | 45 CFR 46 Subparts B, C, D |
Agreement Sections
| Section | Must Include |
|---|---|
| Parties and Definitions | Sponsor, institution, PI; define Study, Protocol, Investigational Product, SAE, Confidential Information |
| Study Description | Protocol incorporated by reference; scope; single vs multi-center |
| Investigator Responsibilities | Conduct per protocol; no deviations except to eliminate immediate hazard; amendment approval workflow |
| IRB and Approvals | No study activities before written IRB approval; continuing review; submissions shared with sponsor |
| Informed Consent | Current IRB-approved forms; qualified designee; no coercion; LAR and assent as applicable |
| Study Personnel | Delegation of authority log; training documentation; PI retains ultimate responsibility |
| Investigational Product | Receipt only from sponsor; storage conditions; accountability logs; no off-protocol use; return/destroy per sponsor |
| Safety Reporting | AE/SAE definitions; sponsor reporting timelines; IRB reporting for unanticipated problems |
| Data Integrity | ALCOA+; source data verification; correction rules; EDC audit trail |
| Records and Retention | Essential documents per ICH GCP § 8; retention per 21 CFR 312.62(c) / 812.140(d), or longer per law/policy |
| Monitoring and Access | Reasonable advance notice; direct source access; HIPAA minimum necessary; corrective actions |
| Regulatory Inspections | Notify sponsor within 24 hours; provide FDA 483 or correspondence within 5 business days |
| Confidentiality | Scope; permitted disclosures to IRB/regulators; term and return/destruction |
| Data and IP Ownership | Sponsor owns study data and results; invention assignment; sample ownership with institutional carve-outs |
| Publications | Sponsor review window; patent delay; multicenter coordination; ICMJE authorship standards |
| Compensation and Budget | FMV/AKS compliance; invoicing; screen fail and early withdrawal rules; startup/closeout costs |
| Financial Disclosure/COI | 21 CFR Part 54 disclosures; update obligations; conflict management |
| Indemnification | Sponsor product liability indemnity; carve-outs for PI/site negligence or noncompliance |
| Insurance | Sponsor clinical trial liability; site professional liability; certificate requirements |
| Term and Termination | For cause and convenience; subject safety wind-down; payment of earned fees |
| Governing Law/Disputes | State law selection; venue or negotiation/mediation steps |
| Compliance | FCPA/UK Bribery Act; export control/OFAC; Sunshine Act reporting |
Exhibits
- [ ] Protocol and amendments
- [ ] Budget and payment schedule
- [ ] Study team roster and qualifications
- [ ] Financial disclosure forms
- [ ] Informed consent/assent forms
- [ ] Institutional policies incorporated by reference
- [ ] Publication policy (if separate)
Default Timelines
Adjust to protocol/IRB policy.
| Event | Default |
|---|---|
| Sponsor notification of SAE | Within 24 hours of awareness |
| IRB submission of unanticipated problems | Per IRB policy, prompt reporting |
| Publication review by sponsor | 45–60 days before submission |
| Patent delay after review | Up to 60–90 days |
Final Checks
- [ ] Parties and governing law match site and sponsor
- [ ] All regulatory citations align with drug/biologic vs device track
- [ ] Consent and privacy requirements align with site policy
- [ ] Payment terms are FMV and AKS compliant
- [ ] Indemnity/insurance reflect institutional limits
- [ ] Every unverified citation marked
[VERIFY]
Troubleshooting
| Issue | Resolution |
|---|---|
| Unclear whether drug or device track applies | Confirm IND (21 CFR 312) vs IDE (21 CFR 812) with sponsor; combination products follow primary mode of action |
| Institution requires its own template | Merge sponsor terms into institutional template; flag conflicts for negotiation |
| Public entity cannot indemnify | Carve out sovereign immunity; shift to insurance-only model with higher certificate minimums |
| PI holds multiple roles (e.g., also sponsor-investigator) | Apply 21 CFR 312.50–312.70 sponsor obligations in addition to investigator duties |
| Budget exceeds FMV benchmarks | Document FMV analysis methodology; adjust per AAMC/PhRMA guidelines to avoid AKS risk |
Guidelines
- Apply the most stringent requirement among federal law, state law, and institutional policy.
- No study activity before IRB approval and full execution if required by the institution.
- Keep confidentiality and publication clauses consistent with multi-center coordination.
- Preserve a clear audit trail for data corrections and monitoring access.
- Flag any unclear regulatory citation with
[VERIFY].
No additional documents ship with this skill.
Related Skills
United States
·
life-sciences
Quality Agreement for Contract Manufacturing
Drafts Quality Agreements for pharmaceutical contract manufacturing. Assigns quality roles between product owners and CMOs under FDA cGMP (21 CFR 210…
United States
·
life-sciences
Promotional Materials Review Policy
Drafts an internal Promotional Materials Review Policy for life sciences and pharmaceutical companies under FDA oversight. Covers promotional review …
United States
·
life-sciences
Pharmaceutical Regulation Compliance Summary
Generates structured pharmaceutical regulatory compliance summaries covering FDA approval pathways, patent/IP intersections (Orange Book, Hatch-Waxma…
United States
·
life-sciences
New Drug Application (NDA)
Drafts an eCTD-compliant New Drug Application (NDA) for FDA submission under 21 CFR Part 314. Compiles clinical trial data, CMC documentation, noncli…
United States
·
life-sciences
Investigator Agreement
Drafts Investigator Agreements for FDA-regulated clinical trials between sponsors and principal investigators. Covers 21 CFR Parts 50, 56, 312/812, I…
Comments
Loading…